ScoreWhy is Jinhe Biotechnology Co., Ltd. ?
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 10.19% and Operating profit at -9.44% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 5.60% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 10.19% and Operating profit at -9.44% over the last 5 years
3
Flat results in Mar 26
- NET PROFIT(HY) At CNY -49.1 MM has Grown at -230.54%
- ROCE(HY) Lowest at 1.69%
- DEBT-EQUITY RATIO (HY) Highest at 83.12 %
4
With ROE of 0.02%, it has a very expensive valuation with a 1.36 Price to Book Value
- Over the past year, while the stock has generated a return of -20.38%, its profits have fallen by -99.5%
- At the current price, the company has a high dividend yield of 2.5
5
Below par performance in long term as well as near term
- Along with generating -20.38% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Jinhe Biotechnology Co., Ltd. for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Jinhe Biotechnology Co., Ltd.
-23.36%
0.91
33.91%
China Shanghai Composite
0.9%
1.20
14.07%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
10.19%
EBIT Growth (5y)
-9.44%
EBIT to Interest (avg)
2.41
Debt to EBITDA (avg)
4.42
Net Debt to Equity (avg)
0.75
Sales to Capital Employed (avg)
0.53
Tax Ratio
98.99%
Dividend Payout Ratio
274.73%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.74%
ROE (avg)
5.60%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
3594
Industry P/E
Price to Book Value
1.57
EV to EBIT
39.85
EV to EBITDA
16.70
EV to Capital Employed
1.33
EV to Sales
1.77
PEG Ratio
NA
Dividend Yield
2.17%
ROCE (Latest)
3.33%
ROE (Latest)
0.02%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 587.21 MM
PRE-TAX PROFIT(Q)
At CNY 99.77 MM has Grown at 607.37%
NET PROFIT(Q)
At CNY 68.77 MM has Grown at 595.37%
RAW MATERIAL COST(Y)
Fallen by -21.12% (YoY
CASH AND EQV(HY)
Highest at CNY 1,540.31 MM
DEBT-EQUITY RATIO
(HY)
Lowest at 81.5 %
OPERATING PROFIT(Q)
Highest at CNY 182.85 MM
OPERATING PROFIT MARGIN(Q)
Highest at 25.91 %
-6What is not working for the Company
NET PROFIT(9M)
At CNY 19.67 MM has Grown at -84.19%
ROCE(HY)
Lowest at 0.89%
Here's what is working for Jinhe Biotechnology Co., Ltd.
Pre-Tax Profit
At CNY 99.77 MM has Grown at 607.37%
over average net sales of the previous four periods of CNY 14.1 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (CNY MM)
Net Profit
At CNY 68.77 MM has Grown at 595.37%
over average net sales of the previous four periods of CNY 9.89 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (CNY MM)
Operating Cash Flow
Highest at CNY 587.21 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Operating Profit
Highest at CNY 182.85 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Operating Profit Margin
Highest at 25.91 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Cash and Eqv
Highest at CNY 1,540.31 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at 81.5 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -21.12% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
